CellForge
Seattle, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $250M
Overview
Developer of an off-the-shelf cell therapy platform targeting oncology and immunology.
OncologyImmunology
Technology Platform
A proprietary allogeneic cell engineering platform that utilizes gene editing to create immune cells resistant to host rejection and with enhanced therapeutic activity.
Funding History
1Total raised:$250M
Series B$250M
Opportunities
Potential to revolutionize cancer and autoimmune treatment with a scalable, cost-effective alternative to autologous cell therapies.
Risk Factors
Clinical risk of allogeneic cell rejection or poor persistence, alongside significant manufacturing and regulatory hurdles.
Competitive Landscape
Competes in the crowded allogeneic cell therapy space against companies like Allogene Therapeutics and Precision BioSciences, requiring superior efficacy or safety data to stand out.